{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-009540","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2024-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.742739+00:00","generated_at":"2026-06-05T01:50:30.827470+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Foghorn Therapeutics 2023 net loss $98.4M, cash $234.1M; FHD-909 IND planned Q2 2024","bullets":["Net loss $98.4M in 2023 vs $108.9M in 2022; collaboration revenue $34.2M, up from $19.2M.","Cash $234.1M at Dec 31, 2023; runway into H1 2026.","FHD-286 AML combo study dose escalation ongoing; first clinical data expected H2 2024.","Lilly selects FHD-909 (BRM inhibitor) for clinical dev; IND filing Q2 2024 for BRG1-mutated NSCLC.","Preclinical data for CBP/EP300 degraders at AACR; IND-enabling studies for CBP degrader by end 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-009540","json":"https://secwatch.observer/filing/0001628280-24-009540.json","markdown":"https://secwatch.observer/filing/0001628280-24-009540.md","text":"https://secwatch.observer/filing/0001628280-24-009540.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828024009540/0001628280-24-009540-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828024009540/fhtx-20240307.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T01:50:30.827470+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1a2704f9fad837fefb49aa7d9b8eca64779cd94a","claim":"Foghorn Therapeutics Inc. reported the year ended December 31, 2023 results: revenue $34.2 million.","evidence_excerpt":"three discovery programs using Foghorn’s proprietary Gene Traffic Control platform. Full Year 2023 Financial Highlights • Collaboration Revenues . Collaboration revenues were $34.2 million for the year ended December 31, 2023, compared to $19.2 million for the year ended December 31, 2022. The increase year-over-year was primarily driven by revenue recognized under","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822462/000162828024009540/0001628280-24-009540-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Revenue","value":"$34.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}